



## Neurocognition and Adaptive Functioning in a Genetic High-Risk Model of Schizophrenia

Ania Fiksinski<sup>1</sup>, Elemi Breetvelt<sup>2</sup>, Jacob Vorstman<sup>3</sup>, Erin Lee<sup>3</sup>, Erik Boot<sup>3</sup>, Lisa Palmer<sup>2</sup>, Nancy Butcher<sup>3</sup>, Eva Chow<sup>3</sup>, Rene Kahn<sup>4</sup>, Anne Bassett<sup>3</sup>

**Institution(s):** UMC Utrecht, Utrecht, The Netherlands <sup>1</sup>, Toronto General Hospital, Toronto, ON, Canada <sup>2</sup>, University of Toronto, Toronto, ON, Canada <sup>3</sup>, Icahn School of Medicine at Mount Sinai, New York, NY, USA <sup>4</sup>

**Background:** Identifying factors that influence functional outcome is an important goal in schizophrenia research. The 22q11.2 deletion syndrome (22q11DS) is a unique genetic model with high risk (20-25%) for schizophrenia. This study aimed to identify potentially targetable domains of neurocognitive functioning associated with functional outcome in adults with 22q11DS. **Methods:** Using data available from a comprehensive battery of 15 neurocognitive tests for 99 adults with 22q11DS (n=43 with schizophrenia) we derived four domains of neurocognition (Verbal Memory, Visual Memory, Motor Performance, and Executive Performance) using a principal component analysis. To investigate the association of these domains with adaptive functioning, we used Vineland Adaptive Behavior Scales (VABS) data available for 84 subjects in a linear regression model that accounted for the effects of schizophrenia status and overall intellectual level. **Results:** The regression model explained 46.8% of the variance in functional outcome ( $p < 0.0001$ ). Executive performance was significantly associated with functional outcome ( $p = 0.048$ ). Age and schizophrenia were also significant factors. The effects of executive performance on functioning did not significantly differ between those with and without psychotic illness. **Conclusions:** The findings provide impetus for further studies to examine the potential of directed (early) interventions targeting Executive Performance to improve long-term adaptive functional outcome in individuals with, or at high-risk for, schizophrenia. Moreover, the neurocognitive test results may benefit caregivers and clinicians by providing insight into the relative strengths and weaknesses of individuals with 22q11DS.